Routine Microaxial Heart Pump Support and Protocolized Pulmonary Artery Catheter Monitoring Versus Standard Care in Heart Attack-Related Cardiogenic Shock (DOUBLE-SHOCK)
20 de agosto de 2026 atualizado por: Leipzig Heart Science gGmbH
Routine Microaxial Flow Pump Versus Radial Access Revascularization Without Routine Microaxial Flow Pump in Infarct-Related Cardiogenic Shock & Routine Pulmonary Artery Catheterization-based Monitoring With Protocolized Hemodynamic Optimization Versus Simplified Monitoring Without Protocolized Hemodynamic Optimization in Infarct-Related Cardiogenic Shock
The goal of this clinical trial is to learn which treatment strategies improve survival in adult patients with acute myocardial infarction complicated by cardiogenic shock (AMI-CS).
The main questions it aims to answer are:
- Does the immediate use of a left-sided microaxial flow pump (Impella) after percutaneous coronary intervention (PCI) improve survival compared to initial medical therapy alone?
- Does protocol-based hemodynamic monitoring and optimization using a pulmonary artery catheter (PAC) improve survival compared to conventional intensive care monitoring?
Researchers will compare four treatment combinations to see if mechanical circulatory support and/or advanced hemodynamic monitoring reduce mortality in AMI-CS patients:
- Microaxial flow pump + pulmonary artery catheter
- Microaxial flow pump + conventional monitoring
- Medical therapy alone + pulmonary artery catheter
- Medical therapy alone + conventional monitoring
Participants will:
- Undergo immediate coronary angiography and PCI upon hospital admission Be randomly assigned to one of four treatment groups
- Receive either immediate implantation of a microaxial flow pump or initial medical therapy with vasoactive agents following PCI
- Be monitored either via pulmonary artery catheter with protocol-based hemodynamic optimization or via conventional intensive care monitoring
- Be followed up at 30 days, 6 months and 12 monthsafter Randomization, with planned annual follow-up assessments for up to 10 years
Visão geral do estudo
Status
Ainda não está recrutando
Tipo de estudo
Intervencional
Inscrição (Estimado)
780
Estágio
- Não aplicável
Contactos e Locais
Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.
Contato de estudo
- Nome: DOUBLE SHOCK Leipzig Heart Science gGmbH
- Número de telefone: +49 341 865 251542
- E-mail: DOUBLE-SHOCK@leipzig-heart.de
Locais de estudo
-
-
Saxony
-
Leipzig, Saxony, Alemanha, 04289
- Heart Center Leipzig at University of Leipzig
-
-
Critérios de participação
Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.
Critérios de elegibilidade
Idades elegíveis para estudo
- Adulto
- Adulto mais velho
Aceita Voluntários Saudáveis
Não
Descrição
Inclusion Criteria:
Cardiogenic shock complicating AMI (STEMI or NSTEMI) plus obligatory all 4 of these:
- Planned immediate angiography and revascularization (preferred PCI)
- Systolic blood pressure <100 mmHg or catecholamines required to maintain pressure >90 mmHg during systole
- Arterial lactate >2.0 mmol/L
- Echocardiogram with LVEF <40% or left ventricular outflow tract velocity time integral (LVOT-VTI) ≤12 cm
Exclusion Criteria:
- Age <18 and >80 years
- Shock duration >12 hours
- Other causes of shock (hypovolemia, sepsis, pulmonary embolism or anaphylaxis).
- Shock due to mechanical complication of AMI
- Witnessed out-of-hospital cardiac arrest (OHCA) with chest compression >10 min in total (cardiac arrest occurring in ambulance or after hospital arrival is NOT an exclusion criterion and witnessed OHCA with duration of chest compression <10 min are also eligible)
- After 390 included patients with OHCA, any OHCA will be an exclusion criterion
- Any unwitnessed OHCA
- Refractory cardiac arrest with ongoing chest compression
- Evidence of severe right ventricular failure
- Severe aorta valve regurgitation/stenosis
- Severe peripheral arterial obstructive disease precluding mAFP placement
- Abnormalities of the aorta precluding mAFP device placement
- Presence of a mechanical aortic valve prosthesis
- Left ventricular thrombus
- Infective endocarditis
- Life expectancy <1 year due to comorbidities
- Mental disorder or language barrier that preclude informed consent
- Known pregnancy
Plano de estudo
Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição fatorial
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Microaxial flow pump + pulmonary artery catheter
Participants in this arm undergo immediate implantation of a left-sided microaxial flow pump (Impella) via the femoral artery following percutaneous coronary intervention (PCI).
The device is used to unload the left ventricle and augment cardiac output until hemodynamic stabilization is achieved.
In addition, participants receive a pulmonary artery catheter (PAC) inserted via a central venous access (jugular, subclavian, or femoral vein) for continuous hemodynamic monitoring and protocol-based optimization of cardiovascular function.
Target parameters include, e.g., cardiac output, pulmonary capillary wedge pressure (PCWP), systemic and pulmonary vascular resistance.
|
Percutaneous implantation of a left-sided microaxial flow pump via the femoral artery following PCI.
The device actively unloads the left ventricle by aspirating blood from the left ventricle and ejecting it into the ascending aorta, thereby augmenting cardiac output.
Implantation occurs immediately after PCI.
Insertion of a pulmonary artery catheter via central venous access (jugular, subclavian, or femoral vein) for continuous hemodynamic monitoring and protocol-based optimization of cardiovascular function.
Measured parameters include cardiac output, pulmonary capillary wedge pressure (PCWP), and systemic and pulmonary vascular resistance.
|
|
Experimental: Microaxial flow pump + conventional monitoring
Participants in this arm undergo immediate implantation of a left-sided microaxial flow pump (Impella) via the femoral artery following percutaneous coronary intervention (PCI).
The device is used to unload the left ventricle and augment cardiac output until hemodynamic stabilization is achieved.
Hemodynamic monitoring is performed using conventional intensive care methods, including arterial blood pressure measurement, central venous catheter, echocardiography, and serial laboratory parameters.
No pulmonary artery catheter is inserted.
|
Percutaneous implantation of a left-sided microaxial flow pump via the femoral artery following PCI.
The device actively unloads the left ventricle by aspirating blood from the left ventricle and ejecting it into the ascending aorta, thereby augmenting cardiac output.
Implantation occurs immediately after PCI.
Standard intensive care hemodynamic monitoring without pulmonary artery catheter, including invasive arterial blood pressure measurement, central venous pressure monitoring, echocardiography, and serial laboratory parameters (e.g., lactate, creatinine, liver enzymes, blood count).
|
|
Comparador Ativo: Medical therapy + pulmonary artery catheter
Participants in this arm receive initial hemodynamic stabilization through guideline-recommended medical therapy following percutaneous coronary intervention (PCI), without immediate implantation of a mechanical circulatory support device.
In case of refractory cardiogenic shock unresponsive to medical therapy, escalation to mechanical circulatory support is permitted at the discretion of the treating physician.
In addition, participants receive a pulmonary artery catheter (PAC) inserted via a central venous access (jugular, subclavian, or femoral vein) for continuous hemodynamic monitoring and protocol-based optimization of cardiovascular function.
Target parameters include e.g., cardiac output, pulmonary capillary wedge pressure (PCWP), systemic and pulmonary vascular resistance.
|
Insertion of a pulmonary artery catheter via central venous access (jugular, subclavian, or femoral vein) for continuous hemodynamic monitoring and protocol-based optimization of cardiovascular function.
Measured parameters include cardiac output, pulmonary capillary wedge pressure (PCWP), and systemic and pulmonary vascular resistance.
Hemodynamic stabilization without hemodynamic protocol by pulmonary artery catheter.
Hemodynamic stabilization through intravenous vasoactive agents, including vasopressors (e.g., norepinephrine) and/or inotropes (e.g., dobutamine), administered according to current clinical guidelines.
Dosage and duration are determined by the treating physician based on hemodynamic response.
In case of refractory cardiogenic shock unresponsive to medical therapy, escalation to mechanical circulatory support is permitted at the discretion of the treating physician.
|
|
Comparador Ativo: Medical therapy + conventional monitoring
Participants in this arm receive initial hemodynamic stabilization through guideline-directed medical therapy following percutaneous coronary intervention (PCI), without immediate implantation of a mechanical circulatory support device.
In case of refractory cardiogenic shock unresponsive to medical therapy, escalation to mechanical circulatory support is permitted at the discretion of the treating physician.
Hemodynamic monitoring is performed using conventional intensive care methods, including arterial blood pressure measurement, central venous catheter, echocardiography, and serial laboratory parameters.
No pulmonary artery catheter is inserted.
All participants receive standard intensive care treatment as clinically indicated.
|
Standard intensive care hemodynamic monitoring without pulmonary artery catheter, including invasive arterial blood pressure measurement, central venous pressure monitoring, echocardiography, and serial laboratory parameters (e.g., lactate, creatinine, liver enzymes, blood count).
Hemodynamic stabilization without hemodynamic protocol by pulmonary artery catheter.
Hemodynamic stabilization through intravenous vasoactive agents, including vasopressors (e.g., norepinephrine) and/or inotropes (e.g., dobutamine), administered according to current clinical guidelines.
Dosage and duration are determined by the treating physician based on hemodynamic response.
In case of refractory cardiogenic shock unresponsive to medical therapy, escalation to mechanical circulatory support is permitted at the discretion of the treating physician.
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
all-cause death
Prazo: 180 days after randomization
|
The primary outcome measure (endpoint) is the time to all-cause death during the first 180 days after randomization in all patients randomized.
|
180 days after randomization
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Lactate clearance
Prazo: 48 hours
|
Number of participants with reduction in arterial lactate measurement from baseline to 48 hours measurement.
|
48 hours
|
|
Time to normalization of lactate
Prazo: from date of randomization until the time in hours to stable normalization of arterial lactate <2 mmol/l.
|
Time in hours to stable normalization of arterial lactate <2 mmol/l.
|
from date of randomization until the time in hours to stable normalization of arterial lactate <2 mmol/l.
|
|
Time to hemodynamic stabilization
Prazo: Time to hemodynamic stabilization from randomization up to 4 weeks.
|
Time to hemodynamic stabilization from randomization up to 4 weeks.
|
|
|
Need for escalation to (additional) MCS
Prazo: from date of randomization up to 4 weeks
|
Number of patients requiring escalation to (additional) MCS from randomization up to 4 weeks.
|
from date of randomization up to 4 weeks
|
|
Vasoactive-inotropic score (VIS)
Prazo: from randomization to ICU discharge which usually occurs within 4 weeks
|
The score has no metric; higher values indicate worse outcomes.
|
from randomization to ICU discharge which usually occurs within 4 weeks
|
|
Need for cardio-pulmonary resuscitation
Prazo: from date of randomization up to 4 weeks
|
Number of patients requiring cardiopulmonary resuscitation.
|
from date of randomization up to 4 weeks
|
|
Length of intensive care unit stay
Prazo: from date of randomization to usually up to 4 weeks.
|
Length of intensive care unit stay in days
|
from date of randomization to usually up to 4 weeks.
|
|
Length of hospitalization
Prazo: from date of randomization to usually up to 6 months
|
Length of hospital stay in days
|
from date of randomization to usually up to 6 months
|
|
Quality of life (EuroQol 5D-5L)
Prazo: 6month, 12 month after randomisation
|
Quality of life measured by the EuroQol 5D-5L questionnaire.
The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression.
Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems.
The patient is asked to indicate his/her health state by ticking the box next to the most appropriate statement in each of the five dimensions.
This decision results in a 1-digit number that expresses the level selected for that dimension.
The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state.
|
6month, 12 month after randomisation
|
|
Time to recurrent myocardial infarction
Prazo: From randomization to recurrent myocardial infarction or end of follow-up, assessed at 30 days, 6 months, and 12 months after randomization
|
From randomization to recurrent myocardial infarction or end of follow-up, assessed at 30 days, 6 months, and 12 months after randomization
|
|
|
Time to rehospitalization for congestive heart failure
Prazo: during the first 30 days, 6 and 12 months after randomization
|
during the first 30 days, 6 and 12 months after randomization
|
|
|
Time to death
Prazo: during the first 30 days and 12 months after randomization
|
during the first 30 days and 12 months after randomization
|
|
|
Use of heart replacement therapy
Prazo: from date of randomization up to 6 months.
|
Need for heart replacement therapy
|
from date of randomization up to 6 months.
|
|
Mortality and heart failure events
Prazo: at 6 and 12 months
|
death, permanent LVAD/HTx and heart failure hospitalization
|
at 6 and 12 months
|
|
Implantable defibrillator
Prazo: from date of randomization up to 12 months.
|
Need for implantable cardiac defibrillator
|
from date of randomization up to 12 months.
|
|
Health-related costs
Prazo: from date of randomization to 6 months
|
Health related costs in € for each intervention.
|
from date of randomization to 6 months
|
|
Mortality
Prazo: From randomization to death from any cause, assessed annually up to 10 years after randomization
|
From randomization to death from any cause, assessed annually up to 10 years after randomization
|
Outras medidas de resultado
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Sustained ventricular arrhythmia requiring cardioversion
Prazo: from date of randomization up to usually 4 weeks
|
Sustained ventricular arrhythmia requiring cardioversion
|
from date of randomization up to usually 4 weeks
|
|
Bradycardia with pacing requirement
Prazo: from date of randomization up to usually 4 weeks.
|
Bradycardia requiring pacing.
|
from date of randomization up to usually 4 weeks.
|
|
Acute kidney injury according to KDIGO criteria
Prazo: from date of randomization up to usually 4 weeks.
|
Acute kidney injury according to KDIGO criteria
|
from date of randomization up to usually 4 weeks.
|
|
Creatinine clearance (assessed by eGFR)
Prazo: From randomization to 72 hours after randomization
|
From randomization to 72 hours after randomization
|
|
|
Requirement for renal replacement therapy
Prazo: from date of randomization up to usually 4 weeks.
|
Acute kidney injury requiring renal replacement therapy.
|
from date of randomization up to usually 4 weeks.
|
|
Major bleeding according to BARC definition (BARC 3-5)
Prazo: from date of randomization up to usually 4 weeks
|
Major bleeding according to BARC 3-5 criteria.
|
from date of randomization up to usually 4 weeks
|
|
Cumulative transfusion need
Prazo: from date of randomization up to 4 weeks.
|
Number of red packed blood cells for transfusion per patient .
|
from date of randomization up to 4 weeks.
|
|
Vascular access site related complications
Prazo: from date of randomization up to 4 weeks.
|
Number of vascular access site related complications.
|
from date of randomization up to 4 weeks.
|
|
Significant hemolysis
Prazo: from date of randomization up to usually 4 weeks.
|
Significant hemolysis is defined as a plasma free hemoglobin >20 mg/dL (or an increase of 20 mg/dL above baseline values before initiation of support) and at least one of the following clinical findings occurring within 72 hours after initiation of support or within 24 (±2) hours of device removal:
|
from date of randomization up to usually 4 weeks.
|
|
Sepsis with positive blood cultures
Prazo: from date of randomization up to usually 4 weeks.
|
Sepsis is defined as: Sepsis is caused by the immune system's response to a serious infection, most commonly bacteria, but also fungi, viruses, and parasites in the blood, urinary tract, lungs, skin, or other tissues. It will be defined as: Positive blood cultures and two or more of the following (SEPSIS-3 criteria):
|
from date of randomization up to usually 4 weeks.
|
|
Stroke
Prazo: from date of randomization up to usually 4 weeks.
|
Stroke will be classified in hemorrhagic (cranial CT, MRI, or autopsy) or non-hemorrhagic. Stroke is defined as an acute new neurological deficit ending in death or lasting longer than 24 hours, and classified by a physician as a stroke.
|
from date of randomization up to usually 4 weeks.
|
|
Thrombocytopenia
Prazo: from date of randomization up to 4 weeks.
|
Thrombocytopenia is defined as platelet count <50,000 platelets per microliter.
|
from date of randomization up to 4 weeks.
|
|
Device malfunction
Prazo: from date of randomization up to 4 weeks.
|
from date of randomization up to 4 weeks.
|
Colaboradores e Investigadores
É aqui que você encontrará pessoas e organizações envolvidas com este estudo.
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Holger Thiele, Prof. Dr. med., Heart Center Leipzig at University of Leipzig
- Investigador principal: Jacob Eifer Møller, Prof DMSc, Copenhagen University Hospital Righospitalet
- Investigador principal: Christian Hassager, Prof. DMSc, Rigshospitalet, Denmark
- Investigador principal: Anne Freund, PD Dr. med., Heart Center Leipzig at Leipzig University
Datas de registro do estudo
Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.
Datas Principais do Estudo
Início do estudo (Estimado)
1 de outubro de 2026
Conclusão Primária (Estimado)
1 de outubro de 2030
Conclusão do estudo (Estimado)
1 de abril de 2037
Datas de inscrição no estudo
Enviado pela primeira vez
3 de julho de 2026
Enviado pela primeira vez que atendeu aos critérios de CQ
7 de agosto de 2026
Primeira postagem (Real)
13 de agosto de 2026
Atualizações de registro de estudo
Última Atualização Postada (Real)
24 de agosto de 2026
Última atualização enviada que atendeu aos critérios de controle de qualidade
20 de agosto de 2026
Última verificação
1 de agosto de 2026
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- DOUBLE-SHOCK Trial
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
NÃO
Descrição do plano IPD
Individual participant data (IPD) will not be shared publicly.
Access to de-identified data may be considered upon reasonable request and subject to approval by the study sponsor and applicable ethics committees.
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Não
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Não
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .